Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 4, 2006, Pages 1404-1409

  Sáez, Carmen ^a   Martínez Brocca, M Asunción ^a   Castilla, Carolina ^a   Soto, Alfonso ^a   Navarro, Elena ^a   Tortolero, María ^b   Pintor Toro, José A ^c   Japón, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c INSTITUTO DE RECURSOS NATURALES Y AGROBIOLOGÍA DE SEVILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; RADIOACTIVE IODINE; IODIDE; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; THYROID NODULE; UNIVERSITY HOSPITAL; ADENOMA; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NODULAR GOITER; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; THYROID TUMOR;

ADENOMA; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GOITER, NODULAR; HUMANS; IMMUNOHISTOCHEMISTRY; IODIDES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; THYROID NEOPLASMS;

EID: 33646025855     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2532     Document Type: Article

References (27)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ 2005 Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Hundahl SA, Fleming ID, Frengen AM, Menck HR 1998 A national cancer data base report on 53856 cases of thyroid carcinoma treated in the US 1985-1995. Cancer 83:2638-2648
3. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463
4. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
5. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K, Ito K, Tanaka S 1999 Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84:4043-4049
6. Lacroix L, Soria JC, Bidart JM, Schlumberger M 2005 Oncogènes et tumeurs de la thyroïde. Bull Cancer 92:37-43
7. Domínguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Toro JA 1998 hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17:2187-2193
8. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S 1999 Structure, expression, and function of human pituitary- transforming gene (PTTG). Mol Endocrinol 13:156-166
9. Ramos-Morales F, Domínguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, Tortolero M 2000 Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19:403-409
10. Zou H, McGarry TJ, Bernal T, Kirschner MW 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285:418-422
11. Sáez C, Japón MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA 1999 hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18:5473-5476
12. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in human pituitary adenomas. J Clin Endocrinol Metab 84:761-767
13. Puri R, Tousson A, Chen L, Kakar SS 2001 Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett 163:131-139
14. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S 2000 Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355:716-719
15. Sáez C, Pereda T, Borrero JJ, Espina A, Romero F, Tortolero M, Pintor-Toro JA, Segura DI, Japón MA 2002 Expression of hpttg proto-oncogene in lymphoid neoplasias. Oncogene 21:8173-8177
16. Heaney AP, Nelson V, Fernando M, Horwitz G 2001 Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab 86:5025-5032
17. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJL, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC, Franklyn JA 2003 Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 88:2341-2347
18. Sobin LH, Wittekind C, eds. 2002 TNM classification of malignant tumors, 6th Ed. New York: Wiley-Liss; 52-56
19. Thyroid Carcinoma Task Force 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 7:202-220
20. Kloos RT 2005 Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 6:323-338
21. Ramaswamy S, Ross KN, Lander ES, Golub TR 2003 A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54
22. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJL 2002 Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244
23. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-3234
24. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N 2003 The sodium-iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48-77
25. Robbins RJ, Schlumberger MJ 2005 The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46(Suppl 1):28S-37S
26. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441
27. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105-112